Company intelligence / Profile preview

Critical Diagnostics

United States

Ownership: Private
Development stage: Other

Overview

Develops and commercializes the Presage ST2 Assay, a biomarker test for risk stratification in chronic heart failure patients. The assay is CE Marked and FDA cleared, with extensive clinical validation in over 50 peer-reviewed studies involving more than 31,000 patients.[2][3]

Therapeutic areas: Cardiovascular
Industry: Protein Biomarker Diagnostics

Partnerships

Health (license agreement, 2016)European distributors: Bestbion dx GmbH (Germany), INyDIA (Spain/Portugal), Eurobio AbCys (France), Savas Medikal (Turkey)

Beyond the preview

Go deeper on Critical Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Critical Diagnostics.

Explore the full profile